Injectafer
Author: Michael Haydock
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Injectafer (ferric carboxymaltose; Vifor/Luitpold Pharmaceuticals/Zeria) is an iron maintenance treatment used to help elevate hemoglobin levels in patients with anemia in chronic kidney disease (CKD). It is administered intravenously and is dissociated into iron and sucrose once in circulation. The iron is transported via transferrin to erythroid precursor cells. Erythroid precursor cells incorporate the iron into hemoglobin as the cell matures into a red blood cell. Iron maintenance therapies like Injectafer have achieved widespread use by improving both the safety and cost-efficiency associated with treating anemia in CKD, reducing the doses of erythropoiesis-stimulating agents required to correct and maintain hemoglobin levels.
TABLE OF CONTENTS
4 Product Profiles
4 Injectafer : Anemia in chronic kidney disease
LIST OF FIGURES
7 Figure 1: Injectafer for anemia in chronic kidney disease – SWOT analysis
8 Figure 2: Datamonitor Healthcare’s drug assessment summary of Injectafer for anemia in chronic kidney disease
9 Figure 3: Datamonitor Healthcare’s drug assessment summary of Injectafer for anemia in chronic kidney disease
11 Figure 4: Injectafer sales for anemia in chronic kidney disease across the US and five major EU markets, by country, 2015–24
LIST OF TABLES
5 Table 1: Injectafer drug profile
6 Table 2: Injectafer Phase III data in anemia in chronic kidney disease
12 Table 3: Injectafer sales for anemia in chronic kidney disease across the US and five major EU markets, by country ($m), 2015–24
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Feraheme 
Sign up to the